Document:

Neuromed Pharmaceuticals, Inc. Special Equity Incentive Plan

 Exhibit 10.51 
 NEUROMED PHARMACEUTICALS INC. 
 Special Equity Incentive Plan 
 This Special Equity Incentive Plan is established by Neuromed Pharmaceuticals Inc., a Delaware corporation (the “Company”). 

1. Purpose. The purpose of this Plan is to enhance the Company’s ability to retain and motivate persons who have made, and are expected to
make, important contributions to the Company by providing a way for the Company to provide a meaningful financial incentive to such persons. 
 2. Definitions. As used in this Plan, the following terms shall have the meanings set forth below: 
 “Award”
shall mean the right to receive a grant of RSUs immediately after the consummation of the Merger, determined in accordance with this Plan and subject to adjustment and the other terms of this Plan. 
 “Award Pool” shall mean the total number of shares of common stock of CombinatoRx issuable upon vesting of the RSUs available for
distribution pursuant to this Plan, which shall equal three percent (3%) of the CombinatoRx Deemed Outstanding Shares (as defined in the Merger Agreement), rounded up or down to the nearest whole share. 
 “Board” shall mean the Board of Directors of the Company. 
 “Code” shall mean the Internal Revenue Code of 1986, as amended. 
 “CombinatoRx” shall mean CombinatoRx, Incorporated, a Delaware corporation. 
 “CombinatoRx Plan”
shall mean the CombinatoRx Amended and Restated 2004 Incentive Plan, as it may be amended from time to time. 
 “Committee”
shall mean, until the consummation of the Merger, the Compensation Committee of the Board and, after the consummation of the Merger, the compensation committee of the board of directors CombinatoRx. 
 “Escrow Agreement” shall mean the Escrow Agreement, dated as of June 30, 2009, among CombinatoRx, Kurt C. Wheeler, as
representative of the Company’s stockholders, and Computershare Trust Company, N.A., as escrow agent, as in effect at the Effective Time (as defined in the Merger Agreement). 
 “Merger” shall mean the merger of PawSox, Inc. with and into the Company contemplated by the Merger Agreement. 
 “Merger Agreement” shall mean the Agreement and Plan of Merger, dated as of June 30, 2009, among CombinatoRx, PawSox, Inc., the
Company, Neuromed Pharmaceuticals Ltd. and Kurt C. Wheeler, as representative of the Company’s stockholders. 

 “Participant” or “Participants” shall mean such employees of the
Company and/or Neuromed Pharmaceuticals Ltd. and members of the Board who may be designated as Participants by the Committee; provided that no Terminated Participant shall be considered a Participant. The Company shall notify each Participant that
he or she has been designated as such by sending to such Participant a memorandum in substantially the form attached hereto as Exhibit B. 
 “Percentage Interest” shall mean the percentage of the Award Pool each Participant shall be entitled to receive upon vesting of the RSUs to be granted under the CombinatoRx Plan upon the consummation of the Merger. The
Percentage Interest for each Participant shall be determined as provided in Section 4. 
 “Plan” shall mean this
Special Equity Incentive Plan, as it may be amended from time to time in accordance with Section 7(b). 
 “RSU” shall
mean a restricted stock unit granted under the CombinatoRx Plan representing the right to receive a share of common stock of CombinatoRx. 
 “Terminated Participant” shall mean a Participant who ceases to be employed by, or serve as a member of the Board of, the Company or Neuromed Pharmaceuticals Ltd. prior to the consummation of the Merger. A Terminated
Participant shall not be entitled to receive any benefits under this Plan. 
 3. Administration. The Committee shall have authority to
grant Awards, designate Participants and determine Percentage Interests and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable in its sole and absolute discretion. The
Committee may construe and interpret the terms of the Plan and any Award entered into under the Plan. The Committee may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent
it shall deem expedient to carry the Plan into effect and it shall be the sole and final judge of such expediency. All decisions by and interpretations of the Committee, including without limitation with respect to tax matters under Section 6,
shall be made in the Committee’s sole and absolute discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. No member of the Board or the Committee shall be liable for any action or
determination relating to or under the Plan. 
 4. Percentage Interest. 
 (a) The Percentage Interest for each Participant as determined by the Committee shall be set forth opposite the Participant’s name on Exhibit
A to this Plan. The sum of the Percentage Interests of all Participants shall not exceed 100%. 
 (b) Exhibit A to this Plan may
be amended by the Committee from time to time as follows: (i) the Committee may amend Exhibit A to this Plan to add Participants and to designate the Percentage Interest of such Participants; (ii) the Committee may amend Exhibit
A to this Plan to increase or decrease the Percentage Interest of any Participant, provided that the Committee may not decrease the Percentage Interest of any Participant (for the avoidance of doubt, other than a Terminated Participant) without
the prior written consent of such Participant; 

 
and (iii) the Committee shall amend Exhibit A to this Plan from time to time to remove Terminated Participants. 
 5. Awards. 
 (a) Each Participant
shall be entitled to an Award under this Plan representing the right to receive a number of RSUs equal to the Percentage Interest for such Participant of the Award Pool (rounded up or down to the nearest whole share, provided that the Company shall
have the authority to effect such rounding in such a manner that the number of shares then being allocated equals the total number of whole shares in the Award Pool). Upon the consummation of the Merger, each Participant shall become entitled to
receive, and CombinatoRx shall issue to each Participant under the CombinatoRx Plan, the RSUs underlying the Award granted to such Participant. 
 (b) The RSUs underlying the Award for each Participant shall be evidenced by a restricted stock unit agreement substantially in the form of Exhibit C-1 attached hereto, in the case of employee Participants, or Exhibit C-2
attached hereto, in the case of non-employee director Participants, which in each case shall be issued under the CombinatoRx Plan to each Participant upon the consummation of the Merger. In the event that the FDA Approval Date (as defined in the
Escrow Agreement) is on or prior to the Second Milestone Date (as defined in the Escrow Agreement), the RSUs underlying an Award shall vest in full on such FDA Approval Date. In the event that the FDA Approval Date does not occur on or prior to the
Second Milestone Date, 50% of the original number of RSUs underlying an Award shall be immediately forfeited. In the event that the FDA Approval Date is on or after the Second Outside Date (as defined in the Escrow Agreement) and on or prior to the
Final Milestone Date (as defined in the Escrow Agreement), the RSUs underlying an Award shall vest with respect to 50% of the original number of shares of common stock of CombinatoRx underlying the RSUs on such FDA Approval Date. In the case of a
non-employee director Participant, in the event that the FDA Approval Date has not occurred on or before Final Milestone Date, but the Participant continues to be a director of CombinatoRx as of such date, then 42.857% of the original number of RSUs
underlying the Award shall vest and the remainder of the RSUs underlying the Award shall be immediately forfeited. In the case of an employee Participant, (i) in the event that the FDA Approval Date has not occurred on or before Final Milestone
Date, then 7.143% of the original number of RSUs underlying the Award shall be immediately forfeited (which, for the avoidance of doubt, shall be in addition to the 50% of the original number of RSUs underlying the Awards that shall have been
forfeited on Second Milestone Date) and (ii) in the event that the Participant remains employed by CombinatoRx or any of its subsidiaries, including without limitation Neuromed Pharmaceuticals, Ltd. on the fifth anniversary of the date of the
consummation of the Merger, then 42.857% of the original number of RSUs underlying the Award shall vest. In the event that an employee Participant ceases to be employed by CombinatoRx or any of its subsidiaries, including without limitation, the
Company or Neuromed Pharmaceuticals Ltd., or a non-employee director Participant ceases to serve as a member of the board of directors of CombinatoRx prior to the date upon which the RSUs vest, any RSUs that are not vested as of the date of such
cessation shall be forfeited. Each Award may contain terms and conditions in addition to those set forth in the Plan. Notwithstanding the foregoing, in the event of a Change in Control (as defined in the forms of restricted stock unit agreement
attached hereto as Exhibits C-1 and C-2) or if the Participant is terminated by the Company without Cause (as defined in the 

 
form of restricted stock unit agreement attached hereto as Exhibit C-1), 42.857% of the original number of RSUs shall become vested immediately prior
to the consummation of such Change in Control or the date of termination, and (x) if the FDA Approval Date occurs prior to Second Milestone Date, an additional 57.143% of the original number of RSUs shall vest as of such FDA Approval Date, or
(y) if the FDA Approval Date occurs on or after Second Outside Date and on or prior to Final Milestone Date, an additional 7.143% of the original number of RSUs shall vest as of such FDA Approval Date. 
 (c) The shares of capital stock to be distributed with respect to the RSUs underlying Awards shall consist of authorized but unissued shares or treasury
shares. 
 6. Miscellaneous. 
 (a) Nature of Plan. This Plan is meant to supplement and work in conjunction with (and not to replace) the Company’s other incentive programs, such as its option plans, severance arrangements and other benefits plans. No amounts
under this Plan shall actually be funded, set aside or otherwise segregated prior to payment. The obligation to pay the amounts contemplated hereunder shall at all times be an unfunded and unsecured obligation of the Company. Participants shall have
the status of general creditors. 
 (b) Amendment; Termination. This Plan may be amended by the Committee, provided that (i) no
amendment that adversely affects the rights of Participants under this Plan in any material respect may be made without the prior written approval of Participants holding a majority of the Percentage Interests outstanding at the time of such
amendment and (ii) after the consummation of the Merger, no amendment that adversely affects the rights of any Participant under this Plan may be made without the prior written approval of such Participant. This Plan may not be terminated on or
prior to the consummation of the Merger without the prior written approval of the Committee and Participants holding a majority of the Percentage Interests outstanding at the time of such termination, provided that this Plan and all outstanding
Awards shall automatically terminate in the event that the Merger Agreement is terminated prior to the consummation of the Merger. This Plan may not be terminated after the consummation of the Merger without the prior written approval of each
Participant. 
 (c) Withholding. If the Company determines that it is obligated to withhold any tax in connection with an Award under
this Plan, the Company may withhold such required amount from such Award and/or from the Participant’s wages or other remuneration. 
 (d) No Right To Employment. This Plan shall not be construed as giving a Participant the right to continued employment with the Company. 
 (e) No Equity Interests. Subject to the provisions of the applicable Award, no Participant shall have any rights as a stockholder with respect to any shares of capital stock to be distributed with respect to an
Award until becoming the record holder of such shares. 
 (f) Transferability. Except as the Committee may, in its sole and absolute
discretion, otherwise determine or provide, the right to receive an Award may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law. 

 (g) Section 409A. This Plan is intended to comply with, or be exempt from,
the provisions of Section 409A of the Code and shall be interpreted consistently therewith. Notwithstanding the foregoing, neither the Company nor the Board (nor the Committee) shall have any liability to a Participant or to any other person in
the event that Section 409A becomes applicable to payments due under the Plan. 
 (h) Governing Law. The
provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the
laws of a jurisdiction other than such state. 
 (i) Assumption by CombinatoRx. This Plan shall be assumed by
CombinatoRx upon the consummation of the Merger, and without limiting the obligations of CombinatoRx under this Plan, CombinatoRx shall thereafter be liable for, and shall assume, by virtue of the Merger, all the obligations and duties of the
Company pursuant to this Agreement. CombinatoRx shall take all corporate action necessary to reserve for issuance a sufficient number of shares of its common stock for delivery under the RSUs to be granted under the CombinatoRx Plan. From and after
the consummation of the Merger, the shares of CombinatoRx common stock to be distributed with respect to RSUs underlying Awards under this Plan shall be covered by CombinatoRx’s registration statement on Form S-8 (Reg. No. 333-135356) or
another effective registration statement on Form S-8 covering the shares of common stock underlying such RSUs, and CombinatoRx shall use its reasonable best efforts to maintain the effectiveness of any such registration statement for so long as such
RSUs remain outstanding. 
 *   *   *CombinatoRx Form of Restricted Stock Unit Agreement  - Neuromed Directors

 Exhibit 10.52 
 COMBINATORX, INCORPORATED 
 Restricted Stock Unit Agreement 
 Granted Under CombinatoRx, Incorporated Amended and Restated 2004 Incentive Plan 
 The undersigned participant (the “Participant”) (i) acknowledges that on _________, 2009, s/he received an award (the
“Award”) of restricted stock units from CombinatoRx, Incorporated (the “Company”) under the Amended and Restated 2004 Incentive Plan (the “Plan”) in respect of an award issued to the Participant under the Neuromed
Pharmaceuticals Inc. Special Equity Incentive Plan, (ii) hereby agrees to the terms of such Award, subject to the terms set forth in the Plan; (iii) further acknowledges receipt of a copy of the Plan as in effect on the date hereof; and
(iv) agrees with the Company as follows: 
 1. Effective Date. This Agreement shall take effect as of __________, 2009,
which is the date of grant of the Award (the “Grant Date”). 
 2. Grant of Award. The Award consists of __________
restricted stock units (individually, an “RSU” and collectively, the “RSUs”). Each RSU represents the right to receive one share of the common stock of the Company, $0.001 par value per share (“Stock”), as provided in
this Agreement. The shares of Stock that are issuable upon vesting of the RSUs evidenced by this Agreement are referred to as “Shares.” 
 3. Provisions of the Plan; Defined Terms. This Award is subject to the provisions of the Plan, which are incorporated herein by reference. A copy of the Plan as in effect on the date of the grant of this Award has been
furnished to the Participant. By accepting this Award, the Participant agrees to be bound by the terms of the Plan and this Agreement. All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is
specified herein. The term “Escrow Agreement” shall mean the Escrow Agreement, dated as of June 30, 2009, among the Company, Kurt C. Wheeler as stockholders’ representative and Computershare Trust Company, N.A., as escrow agent.

 4. Nontransferability of RSUs. The RSUs acquired by the Participant pursuant to this Agreement shall not be sold,
transferred, pledged, assigned or otherwise encumbered or disposed of except as provided below and in the Plan. 
 5. Forfeiture
Risk. If the Participant ceases to serve as a member of the board of directors of the Company (the “Board”), for any reason (including by death or disability), any unvested RSUs (after the application of Section 6 of this
Agreement and any other applicable provision contained in this Agreement) and any Dividend Equivalents (as defined below) paid with respect thereto shall be automatically and immediately forfeited as of the date of such termination. 
 6. Vesting of RSUs. The RSUs acquired hereunder shall vest in accordance with the provisions of this Section 6 and applicable
provisions of the Plan, as follows: 
 (a) In the event that the FDA Approval Date (as defined in the Escrow Agreement) is on or prior to the
Second Milestone Date (as defined in the Escrow Agreement), 

 
this Award shall become immediately vested in full on such FDA Approval Date. In the event that the FDA Approval Date does not occur on or prior to the
Second Milestone Date, 50% of the original number of RSUs (and any Dividend Equivalents (as defined below) paid with respect thereto) shall be immediately forfeited on the Second Outside Date (as defined in the Escrow Agreement). In the event that
the FDA Approval Date is on or after the Second Outside Date and on or prior to the Final Milestone Date (as defined in the Escrow Agreement), this Award shall become vested as to 50% of the original number of RSUs on such FDA Approval Date. In the
event that the FDA Approval Date does not occur on or prior to the Final Milestone Date, but the Participant continues to serve as a member of the Board on the Final Milestone Date, then 42.857% of the original number of RSUs (and any Dividend
Equivalents paid with respect thereto) shall vest and the remainder of the RSUs (and any Dividend Equivalents paid with respect thereto) shall be immediately forfeited on the Final Outside Date. 
 (b) Notwithstanding Section 5, Section 6(a) and any other provision of this Agreement or the Plan, upon the occurrence of a Change in Control
(as defined below) prior to the FDA Approval Date, then (i) 42.857% of the original number of RSUs (and any Dividend Equivalents paid with respect thereto) shall become vested immediately prior to the consummation of such Change in Control, and
(ii) subject to the terms of this Agreement, (A) if the FDA Approval Date occurs prior to the Second Milestone Date, an additional 57.143% of the original number of RSUs (and any Dividend Equivalents paid with respect thereto) shall vest
as of such FDA Approval Date, or (B) if the FDA Approval Date occurs on or after the Second Outside Date and on or prior to the Final Milestone Date, an additional 7.143% of the original number of RSUs (and any Dividend Equivalents paid with
respect thereto) shall vest as of such FDA Approval Date. 
 (c) For purposes of this Agreement, “Change in Control” shall mean:
(i) a sale, merger or consolidation after which securities possessing more than fifty (50%) percent of the total combined voting power of the Company’s outstanding securities have been transferred to or acquired by a person or persons
different from the persons who held such percentage of the total combined voting power immediately prior to such transaction; or (ii) the sale, transfer or other disposition of all or substantially all of the Company’s assets to one or
more persons (other than a wholly owned subsidiary of the Company or a parent company whose stock ownership after the transaction is the same as the Company’s ownership before the transaction); or (iii) an acquisition, merger or similar
transaction or a divestiture of a substantial portion of the Company’s business after which the role of the Participant is not substantially the same as such role prior to the transaction. 
 7. Issuance of Shares. 
 (a)
Subject to the terms of the Plan and this Award, each RSU entitles the Participant to receive one share of Stock as soon as reasonably practicable following the vesting of the RSU, but in no event later than two and one-half months after the end of
the year in which the vesting date occurs. 
 (b) The Shares shall be issued and delivered to the Participant in accordance with
Section 3(a) upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such issuance and with the requirements 

  

 2 

 
hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Participant. 
 (c) Notwithstanding anything to the contrary herein or in the Plan, if the Participant is a “specified employee” within the meaning of
Section 409A of the Code, and if any issuance of Shares hereunder is subject to the rule under Section 409A(a)(2)(B)(i) of the Code, then such issuance of Shares shall be delayed until the earlier of (i) the date that is six months
and one day after the Participant has a “separation from service” as defined in Section 409A of the Code or (ii) the death of the Participant. 
 8. Stockholder Rights, Dividends, etc. Until such time as shares of Stock are issued to the Participant pursuant to Section 7(a), the Participant shall have no rights as a stockholder with respect
to any Shares underlying the RSUs, including, but not limited to, any voting rights, provided, however, that any dividends or other distributions paid with respect to the Shares underlying the RSUs (“Dividend Equivalents”) shall
accrue and shall be converted into additional RSUs based on the closing price of the Stock on any such distribution date and any such additional RSUs shall be subject to the same conditions and restrictions as are the RSUs with respect to which they
were paid. 
 9. Certain Tax Matters. The Participant expressly acknowledges the following: 
 (a) The Participant acknowledges that no election under Section 83(b) of the Code may be filed with respect to this Award. 
 (b) In circumstances in which tax withholding is applicable upon the vesting of the RSUs acquired hereunder, the Company shall retain from the Shares
otherwise deliverable to the Participant a number of Shares having a fair market value (as determined by the Board) equal to the Participant’s tax obligation; provided, however, that the total tax withholding using Shares may not exceed the
Company’s statutory minimum withholding obligation. Notwithstanding the foregoing, the Company may, in its sole discretion, require the Participant to satisfy the withholding obligation with cash. 
 10. Changes in Capitalization; Reorganization Events. 
 (a) Changes in Capitalization. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in
capitalization or event, or any dividend or distribution to holders of Stock other than an ordinary cash dividend, the number of shares of Stock subject to this Award shall be equitably adjusted by the Company in the manner determined by the Board.

 (b) Reorganization Event. Upon the occurrence of a Reorganization Event (as defined below), the Board shall provide that this Award
shall be assumed, or an equivalent award shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof). For purposes hereof, this Award shall be considered assumed if, following consummation of the Reorganization Event,
this Award represents the right to receive, for each Share issuable in respect of the RSUs immediately prior to the consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the
Reorganization Event by holders of Stock for each share of Stock held immediately prior to the 

  

 3 

 
consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a
majority of the outstanding shares of Stock); provided, however, that if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate
thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be delivered by the Company in respect of each RSU to consist solely of common stock of the acquiring or succeeding corporation
(or an affiliate thereof) equivalent in fair market value to the per share consideration received by holders of outstanding shares of Stock as a result of the Reorganization Event. Notwithstanding the foregoing, if the acquiring or succeeding
corporation (or an affiliate thereof) does not agree to assume, or substitute for, this Award, the consideration to be delivered by the Company in respect of each of the RSUs, in lieu of the Shares, shall consist of a cash payment equal to the fair
market value of the consideration received as a result of the Reorganization Event by holders of Stock for each share of Stock held immediately prior to the consummation of the Reorganization Event. In the event of a liquidation or dissolution of
the Company, the consideration to be delivered in respect of each of the RSUs shall consist of, in lieu of the Shares, the consideration received as a result of such liquidation or dissolution by holders of Stock for each share of Stock held
immediately prior to such liquidation or dissolution. As used herein, “Reorganization Event” means (i) any merger or consolidation of the Company with or into another entity as a result of which all of the Stock of the Company is
converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (ii) any transfer or disposition of all of the Stock of the Company for cash, securities or other property pursuant to a share exchange or
other transaction or (iii) any liquidation or dissolution of the Company. 
 11. Miscellaneous. 
 (a) Notice hereunder shall be given to the Company at its principal place of business and shall be given to the Participant at the address set forth
below, or in either case, at such other address as one party may subsequently furnish to the other party in writing. 
 (b) This Award does
not confer upon the Participant any rights with respect to continuation of service as a member of the Board. 
  

 4 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first written
above. 
  

			
	COMBINATORX, INCORPORATED
		
	By:	 	 
		 	 Name:
 Title:

  

	
	
	
	  
	[NAME OF PARTICIPANT]

  

			
		
	Address:	 	 
		 	
		 	 

  

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}]]